Semaglutide After the Patent Expiry: Every Generic Option in India
Novo Nordisk's semaglutide patent expired in India on 20 March 2026. Within weeks, 40-plus DCGI-approved versions launched at up to 90 percent lower prices. This is the full map: every major brand, what it costs, and which makers have published real Indian trial data.
ALTRcare Medical Team
Clinical Editorial
On 20 March 2026, Novo Nordisk's core Indian patent on semaglutide (the molecule behind Ozempic and Wegovy) expired. The next morning, Indian manufacturers began 'Day 1' launches, and by mid-2026 more than 40 DCGI-approved semaglutide brands are on the market, priced from ₹1,290 a month against the ₹10,000-plus the branded versions cost a year earlier. This page maps the whole landscape: who makes what, what it costs, how these versions were approved, and how to choose between them.
What actually changed in March 2026
Patent expiry did not make semaglutide over-the-counter, cheaper by decree, or different as a molecule. It made one thing legal: other companies manufacturing and selling the same molecule under their own brands. Competition did the rest. Prices for generic versions landed 80 to 90 percent below the old branded pricing, and Novo Nordisk responded within days, cutting Ozempic and Wegovy by up to 48 percent in India so that both now start around ₹5,660 a month at the 0.25 mg dose. Semaglutide remains a Schedule H prescription medicine in every form.
Every major generic, in one table
| Maker | Brand names | Format | Monthly cost (from) | Indication labels |
|---|---|---|---|---|
| Eris / Natco | SUNDAE, Semanat, Semafull | Multi-dose vial | ₹880 to ₹1,290 (₹220 to ₹325 per weekly shot) | Diabetes and obesity |
| Glenmark | GLIPIQ | Vial | About ₹1,300 | Diabetes |
| Sun Pharma | Noveltreat, Sematrinity | Pre-filled pen | From ₹750 | Noveltreat for obesity, Sematrinity for diabetes |
| Alkem | Semasize, Obesema, Hepaglide | Disposable 4-dose pen; reusable pen for higher doses | ₹1,800 (₹450 per week) | Diabetes and chronic weight management |
| Zydus (co-marketed by Lupin, Torrent) | Semaglyn, Mashema, Alterme, Semanext, Livarise | Reusable cartridge pen | About ₹2,200 | Diabetes and obesity |
| MSN Labs | Semabest | Pen | ₹3,990 flat | Diabetes |
| Dr. Reddy's (with USV) | Obeda, Usema | Disposable pen | About ₹4,200 | Diabetes |
| Torrent | Sembolic, Semalix | Injectable and oral tablet | Varies; Semalix is the first generic oral semaglutide | Diabetes and obesity |
| Mankind | Samakind | Pen | Varies | Diabetes and obesity |
These are not 'copies rushed to market': how CDSCO approved them
Here is the detail most coverage misses. In the US, a generic is approved through the Abbreviated New Drug Application route, which mainly requires proving bioequivalence. India's CDSCO approved these semaglutide products under the Subsequent New Drug pathway, which required completed Phase 3 clinical trials in Indian patients before approval. Every serious entrant ran a real trial, which is a higher evidentiary bar than most generics anywhere in the world have to clear.
The Alkem SIZE-DM trial, as a worked example
Alkem's semaglutide (sold as Semasize, Obesema and Hepaglide) went through the SIZE-DM study: a Phase 3, multicenter, randomized, active-controlled trial across 23 tertiary care centres in India, registered with the Clinical Trials Registry of India (CTRI/2025/02/081490). 320 adults with type 2 diabetes inadequately controlled on metformin were randomized 1:1 to Alkem's semaglutide or Novo Nordisk's innovator semaglutide, titrated from 0.25 mg to 2 mg weekly over 24 weeks; 313 completed. Both arms achieved a mean HbA1c reduction of 2.20 percent, and the generic demonstrated non-inferiority to the innovator on the primary endpoint, with comparable safety. In plain language: tested head-to-head against the original, in Indian patients, and it matched.
How to read the field beyond Alkem
Dr. Reddy's has published Indian Phase 3 data for Obeda, and Natco, Sun Pharma and Zydus have trial records behind their approvals. Some smaller entrants cleared CDSCO with thinner public documentation. A reasonable rule many physicians use: prefer brands whose trial data you or your doctor can actually read.
Vial, disposable pen, or reusable pen?
The format decides both price and practicality. Vials (Natco, Eris, Glenmark) are the cheapest but require drawing up each dose with a syringe, which suits some patients and puts off others. Disposable pre-filled pens (Alkem, Sun, Dr. Reddy's) work like the branded pens: dial and inject, throw away after four doses. Reusable cartridge pens (Zydus Semaglyn, Alkem's higher-dose option) let you replace only the medication cartridge, which cuts long-term cost at maintenance doses. If self-injecting with a syringe sounds daunting, the ₹500 to ₹900 monthly premium for a pen is usually worth it for adherence alone.
Generic semaglutide plus a doctor, from ₹3,499 a month
ALTRcare's semaglutide program uses DCGI-approved, Indian-trial-backed medication and bundles the prescribing doctor, titration reviews and follow-up into one monthly price. Take the free 2-minute assessment to see if you qualify.
What has not changed
- Prescription requirement. Every version is Schedule H. A seller offering any semaglutide without a prescription is breaking the law, and grey-market and counterfeit products remain the biggest real-world risk in this market.
- The medicine itself. Same molecule, same weekly titration from 0.25 mg upward, same side-effect profile, same need for medical supervision and baseline blood work.
- Tirzepatide's patent. The expiry applies to semaglutide only. Eli Lilly's tirzepatide (Mounjaro, Yurpeak) patents run well into the 2030s, so no legal generic tirzepatide exists.
- Rybelsus pricing. Novo Nordisk cut its injectable prices but announced no equivalent cut for oral Rybelsus, though Torrent's Semalix now offers a generic oral alternative.
How to choose, practically
Budget first, format second, data third, availability last. If cost is the binding constraint, a vial at ₹1,290 a month makes therapy viable for people it never was before. If you want pen convenience with published head-to-head data, Alkem's Semasize at ₹1,800 is currently the strongest price-to-evidence combination. If you expect to sit at higher maintenance doses for a year or more, a reusable pen system may cost less over the full journey. Whatever you shortlist, the actual selection belongs to your prescribing doctor, who also knows what your local pharmacies reliably stock.
Key takeaways
- Semaglutide's Indian patent expired 20 March 2026; 40-plus DCGI-approved brands launched within months.
- Generic prices start at ₹1,290 a month (vials) and ₹1,800 a month for Alkem's Semasize pen, versus ₹5,660-plus for Ozempic and Wegovy after their April 2026 price cut.
- India's approvals required Phase 3 trials in Indian patients; Alkem's SIZE-DM trial showed non-inferiority to the Novo Nordisk original head-to-head.
- Nothing changed about the prescription requirement, the titration, or the need for medical supervision.
- Tirzepatide has no generics and will not until well into the 2030s.
Frequently asked questions
When did semaglutide go off-patent in India?
Novo Nordisk's core Indian patent on semaglutide expired on 20 March 2026, and the first generic launches began on 21 March 2026.
Is generic semaglutide as effective as Ozempic?
The DCGI-approved generics were required to complete Phase 3 trials in Indian patients before approval. Alkem's SIZE-DM trial compared its semaglutide directly against the Novo Nordisk original in 320 patients and demonstrated non-inferiority, with both arms reducing HbA1c by a mean of 2.20 percent over 24 weeks.
What is the cheapest generic semaglutide in India?
Vial formats are cheapest: Eris SUNDAE from about ₹220 per weekly shot and Natco Semanat from about ₹1,290 per month. The cheapest widely available pen is Sun Pharma's Noveltreat from ₹750, with Alkem's Semasize from ₹1,800 a month.
Is there a generic version of Wegovy specifically?
Wegovy is a brand of semaglutide with an obesity indication. Several Indian generics carry the same chronic weight management indication, including Alkem's Obesema, Sun Pharma's Noveltreat, and Zydus and Eris brands, at a fraction of Wegovy's price.
Did tirzepatide (Mounjaro) also go off-patent?
No. The March 2026 expiry applied to semaglutide only. Eli Lilly's tirzepatide patents in India extend well into the 2030s, so Mounjaro and Yurpeak have no generic competition.
Do I still need a prescription for generic semaglutide?
Yes. Every semaglutide product in India, branded or generic, injectable or oral, is a Schedule H prescription medicine requiring a valid doctor's prescription.
Ready to take the next step?
Take the free 2-minute eligibility assessment. A doctor reviews it before anything is prescribed — no obligation.
This article is for general educational purposes and is not a substitute for personalised medical advice. GLP-1 medications are prescription-only and not suitable for everyone. Always consult a qualified doctor before starting, changing, or stopping any treatment.
